A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer...

Gespeichert in:

Veröffentlicht in:	BMC cancer 12(2012) Artikel-Nummer 108, 6 Seiten
Personen und Körperschaften:	Berger, Anne Katrin (VerfasserIn), Abel, Ulrich (VerfasserIn), Kloor, Matthias (VerfasserIn), Ose, Jennifer (VerfasserIn), Weber, Tim (VerfasserIn), Stange, Annika (VerfasserIn), Haag, Georg Martin (VerfasserIn), Haberkorn, Uwe (VerfasserIn), Jäger, Dirk (VerfasserIn)
Titel:	A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial/ Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger
Format:	E-Book-Kapitel
Sprache:	Englisch
veröffentlicht:	22 March 2012
Gesamtaufnahme:	: BMC cancer, 12(2012) Artikel-Nummer 108, 6 Seiten , volume:12
Schlagwörter:	18F-FDG PET CT Cetuximab Colorectal cancer Metabolic imaging Metastases
Quelle:	Verbunddaten SWB Lizenzfreie Online-Ressourcen

Details
Zusammenfassung:	The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes.
Beschreibung:	Gesehen am 25.04.2018
Umfang:	6
ISSN:	1471-2407
DOI:	10.1186/1471-2407-12-108